Meyer 2026H1: Medical Equipment Business Revenue RMB 194 Million, Down 5.12% Year-on-Year

Source: MeiYa Optoelectronic 2026 Semi-Annual Report

H1 revenue was RMB 1.066 billion / Net profit attributable to shareholders of the parent company was RMB 315 million / Net profit attributable to shareholders of the parent company excluding non-recurring gains and losses was RMB 293 million

DentalGoodNews｜Meyer (002690) released its 2026 semi-annual report on August 26, 2026. During the reporting period, the company achieved operating revenue of RMB 1.066 billion, a year-on-year increase of 4.20%; net profit attributable to shareholders of the listed company was RMB 315 million, up 4.03% year-on-year; however, net profit attributable to shareholders of the listed company excluding non-recurring gains and losses was RMB 293 million, down 0.68% year-on-year, indicating a slight decline in core business profitability.

Source: MeiYa Optoelectronic 2026 Semi-Annual Report

In terms of main business, the company focuses on three major segments: food safety, medical health, and renewable resources. Color sorter business revenue was RMB 781 million, up 5.22% year-on-year; medical equipment business revenue was RMB 194 million, down 5.12% year-on-year, with a gross margin of 51.53%, up 3.08 percentage points year-on-year. The financial report noted that the decline in medical-related business revenue was mainly affected by the broader environment, as the domestic oral industry in which the company operates remains in a period of cyclical downturn. According to previous reports by DGN, Meyer's medical equipment business revenue in 2025 had already declined 9.75% year-on-year, and the pressure on the domestic oral equipment market has continued into the current period.

During the reporting period, the company's export revenue was RMB 258 million, up 11.49% year-on-year, with a gross margin of 65.98%, up 1.38 percentage points year-on-year. Among this, medical equipment export revenue was RMB 31 million, up more than 100% year-on-year.

Source: MeiYa Optoelectronic 2026 Semi-Annual Report

In terms of earnings quality, the company's net cash flow from operating activities was RMB 267 million, down 32.07% year-on-year, mainly due to increased cash payments for purchasing goods, receiving services, and employee compensation; R&D investment during the period was RMB 67.4177 million, down 3.69% year-on-year. Financial expenses were RMB 22.0582 million, up 192.47% year-on-year, mainly due to exchange gains and losses arising from currency fluctuations on the company's foreign currency monetary items. In addition, the company's net cash flow from investing activities was RMB 715 million, up 73.23% year-on-year, mainly due to reduced principal payments for cash management using temporarily idle funds during the period; cash and cash equivalents increased by RMB 341 million, up 82.29% year-on-year.

Furthermore, according to previous reports by DGN, the trade secret dispute case between Meyer and Hefei Dengtefei Medical Equipment Co., Ltd. has received a final judgment from the Supreme People's Court, requiring Dengtefei to compensate Meyer RMB 198 million in economic losses and RMB 958,500 in reasonable legal expenses. As of the end of this reporting period, the company has cumulatively received RMB 24.0985 million in compensation from Dengtefei and other defendants through court enforcement, and the judgment is still being executed.